Hyperpolarized Pyruvate Injection in Subjects With Prostate Cancer

October 1, 2015 updated by: Charles Ryan, University of California, San Francisco

A Phase 1 Ascending-dose Study to Assess the Safety and Tolerability and Imaging Potential of Hyperpolarized Pyruvate (13C) Injection in Subjects With Prostate Cancer

Current imaging options do not assess prostate cancer well. This study will combine two magnetic resonance imaging modalities, MRI and MRSI, in order to determine the utility to physicians and patients with prostate cancer in making treatment decisions and seeing how well various types of treatment work. Hyperpolarized pyruvate (13C) is an investigational product that may enhance the imaging capability of MRI and MRSI. Hyperpolarized pyruvate will be injected into the body to determine how it is metabolized and how it's metabolism can be assessed using MR imaging.

The purpose of this study is to determine the safety and metabolism of hyperpolarized pyruvate in humans, and how this can be used to increase the effectiveness of MR imaging with regards to patient care.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This is a phase 1 clinical study of an investigational medicinal product (IMP), hyperpolarized Pyruvate (13C) Injection. The study includes the acquisition of magnetic resonance (MR) data and will be performed in men with prostate cancer and intact prostates.

A standard dose-escalation design will be used; initially, 6 subjects will receive IMP at each dose level. As data on both the dynamics of arrival of the IMP and potential imaging efficacy are needed at each dose level, requiring the use of separate MR acquisition sequences, a modified 3+3 design will be applied in each dose cohort. The first 3 subjects will undergo dynamic 13C imaging to define the kinetics of delivery and metabolism of IMP, and the second 3 subjects will undergo 13C MR spectroscopic imaging (MRSI) to obtain 3-dimensional (3-D) spatial information about metabolism of IMP in regions of the prostate with and without cancer involvement.

After the apparent maximum tolerated dose (MTD) has been established, there will be an expansion of the 3-D imaging cohort to 6 subjects (9 subjects in total at this dose level) to obtain additional information regarding safety at the MTD. If >2 subjects from this cohort of 9 subjects experience a dose-limiting toxicity (DLT), the next lower dose will be defined as the MTD. At the dose level with the highest contrast to noise ratio (dose level less than or equal to the MTD) there will be an expansion of the imaging cohort to include another 15 subjects for a total of 18 subjects who undergo 13C 3-D scanning at this dose, to obtain exploratory information concerning the time course and SNR (signal to noise ratio) of the presence of hyperpolarized [1 13C] pyruvate and its metabolites in regions of cancer and benign prostate tissues. The information provided by these data will be used to develop the MR imaging protocol for future clinical trials that will seek to address the sensitivity and specificity of the technology.

Study Type

Interventional

Enrollment (Actual)

31

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • San Francisco, California, United States, 94143
        • University of California San Francisco

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

INCLUSION CRITERIA:

  1. The subject has biopsy-proven prostate cancer and is either undergoing active surveillance ("watchful waiting") or pre primary local treatment for prostate cancer (i.e., prior to either radiation therapy or radical prostatectomy).
  2. The subject is able and willing to comply with study procedures and provide signed and dated informed consent.
  3. The subject has concordant MRI/1H MRSI findings from a prior MR staging exam performed within 8 weeks of the 13C MRSI exam performed in this study with IMP, or is willing to undergo MRI/1H MRSI in connection with the study exam.
  4. Negative test for hepatitis B and hepatitis C.
  5. Eastern Cooperative Oncology Group Performance Status of 0 or 1.

  6. Laboratory criteria for protocol entry:

    • Absolute neutrophil count (ANC) >/= 1500 cells/microLiters
    • Hemoglobin >/= 9.0 gm/dL
    • Platelets >/= 100,000 cells/microLiters
    • Estimated creatinine clearance >/= 60 mL/min (by the Cockcroft Gault equation)
    • Bilirubin within normal range
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) within normal range
  7. Willing to use contraception during and for 1 month after completion of the study.

EXCLUSION CRITERIA:

  1. The subject has received, or is scheduled to receive, another IMP from 1 month before to 1 month after inclusion in this study.
  2. Current or prior androgen deprivation therapy; previous use of a 5-alpha reductase inhibitor is allowed, provided it was discontinued at least 1 month prior to study entry.
  3. Poorly controlled hypertension, with blood pressure at study entry >150/90.
  4. Contraindication for or inability to tolerate MRI examination.
  5. Prostate biopsy within 12 weeks prior to study entry.
  6. BMI of less than 18.5 or greater than 32. At the 0.43 ml/kg dose, subject body weight should be less than or equal to 100 kg owing to limitations in the amount of IMP available.
  7. Congestive heart failure or New York Heart Association (NYHA) status >2.
  8. A past or present medical history of clinically significant electrocardiogram (EKG) abnormalities, including QT prolongation, a family history of prolonged QT interval syndrome, or myocardial infarction (MI) less than 1 year ago with ensuing unstable EKG.
  9. Ongoing acute or chronic pulmonary bronchospastic disease, including a history of chronic obstructive pulmonary disease or asthma, with an exacerbation within the past year.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 1
0.14 ml/kg bw - hyperpolarized pyruvate
Drug: Hyperpolarized Pyruvate (13C) injection
single hyperpolarized pyruvate IV (intravenous) injection followed by MR imaging scans (MRI and MRSI)
Other Names:
  • [1-13C]pyruvic acid
  • AH111710
Experimental: 2
0.28 ml/kg bw - hyperpolarized pyruvate
Drug: Hyperpolarized Pyruvate (13C) injection
single hyperpolarized pyruvate IV (intravenous) injection followed by MR imaging scans (MRI and MRSI)
Other Names:
  • [1-13C]pyruvic acid
  • AH111710
Experimental: 3
0.43 ml/kg bw - hyperpolarized pyruvate
Drug: Hyperpolarized Pyruvate (13C) injection
single hyperpolarized pyruvate IV (intravenous) injection followed by MR imaging scans (MRI and MRSI)
Other Names:
  • [1-13C]pyruvic acid
  • AH111710

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants with Adverse Events as a Measure of Safety and Tolerability.
Time Frame: 7 days

Assessment of the occurrence of clinically significant changes in safety variables from baseline. Safety endpoints include monitoring for the occurrence of treatment-emergent AEs. Monitoring will occur to evaluate for dose-limiting toxicity.

Dose-Limiting Toxicity (DLT) is defined as any toxicity greater than or equal to grade 2, 3 or 4, attributable to the imaging agent and occurring within 7 days after administration. The maximum tolerated dose will be the dose level at which <33% DLT occurs.
7 days

Secondary Outcome Measures

Outcome Measure
Measure Description
to determine the time course and imaging window that provides the best signal-to-noise ratio (SNR) of the presence of hyperpolarized pyruvate (13C).
The optimum 13C imaging window for maximizing lactate SNR will be determined as the period of time after injection in which hyperpolarized lactate reaches a maximal plateau in the prostate. This plateau results from opposing processes of lactate production from pyruvate and T1 decay (for pre-clinical studies this plateau occurred approximately between 35 and 55 seconds).
To determine the kinetics and prostate metabolism of hyperpolarized pyruvate (13C)
For the subjects receiving 3-D 13C spectroscopic imaging (the second 3 subjects per dose cohort as well as the expansion cohorts), a fast 13C MRSI sequence will be used to acquire data from the prostate at a time defined by the kinetic studies (approximately 40 seconds after intravenous administration of hyperpolarized pyruvate).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of California, San Francisco

Collaborators

GE Healthcare

Investigators

  • Principal Investigator: Charles Ryan, M.D., University of California, San Francisco

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2010

Primary Completion (Actual)

November 1, 2011

Study Completion (Actual)

August 1, 2013

Study Registration Dates

First Submitted

October 13, 2010

First Submitted That Met QC Criteria

October 26, 2010

First Posted (Estimate)

October 28, 2010

Study Record Updates

Last Update Posted (Estimate)

October 5, 2015

Last Update Submitted That Met QC Criteria

October 1, 2015

Last Verified

August 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 085517

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Prostate Cancer

Clinical Trials on Hyperpolarized Pyruvate (13C) injection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe